Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study
CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study

Shares of Corcept Therapeutics CORT were up 13.7% on Jan. 22, after the company announced that the phase III ROSELLA study, which evaluated its pipeline candidate, relacorilant in combination with

Dollar General Enhances Shopping Speed With Expanded myDG Delivery
Dollar General Enhances Shopping Speed With Expanded myDG Delivery

Dollar General Corporation DG is advancing its retail strategy by expanding myDG Delivery to improve shopping speed and convenience. The same-day delivery service, available through the DG app and

Nokia to Report Q4 Earnings: Will Revenues Boost Its Future Growth?
Nokia to Report Q4 Earnings: Will Revenues Boost Its Future Growth?

Nokia Corporation NOK is set to report fourth-quarter 2025 results on Jan. 29, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 16.67%. It pulled

Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?
Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?

CorMedix CRMD has been riding on the success of its lead product, DefenCath (taurolidine plus heparin), which was approved by the FDA in 2023 as the first and only antimicrobial catheter lock

PayPal to Expand Agentic Commerce: Will it Boost Revenue Growth?
PayPal to Expand Agentic Commerce: Will it Boost Revenue Growth?

PayPal Holdings, Inc. PYPL announced it has agreed to acquire Cymbio, a platform for multi-channel orchestration that enables brands to sell across agentic surfaces like Microsoft Copilot and

Colgate's Q4 Earnings Around the Corner: What Investors Should Know?
Colgate's Q4 Earnings Around the Corner: What Investors Should Know?

Colgate-Palmolive Company CL is expected to register top-line growth when it reports fourth-quarter 2025 results on Jan. 30, before the opening bell. The Zacks Consensus Estimate for fourth-quarter

Why QUBT Stock Is Outperforming the Industry Despite Near-Term Risks
Why QUBT Stock Is Outperforming the Industry Despite Near-Term Risks

Quantum Computing Inc. QUBT, also known as QCi, has strengthened its financial position by raising more than $1.5 billion in capital, giving it ample resources to invest in technology development

NVR Is Set to Report Q4 Earnings: What's in Store for the Stock?
NVR Is Set to Report Q4 Earnings: What's in Store for the Stock?

NVR, Inc. NVR is expected to report lower earnings in the fourth quarter of 2025. Homebuilding revenues are also likely to have decreased on a year-over-year basis, given soft demand, elevated

Software Stocks Have Plunged: Steals or Traps?
Software Stocks Have Plunged: Steals or Traps?
  • (0:15) - Where Should You Invest Within The Software Industry
  • (2:40) - Tracey's Top Stock Picks For Your Watchlist Right Now
  • (15:30) - Episode Roundup: TWLO, CRM, ADBE
  • [email protected]

 

Welcome

PepsiCo vs. Vita Coco: Which Beverage Stock Offers Better Growth?
PepsiCo vs. Vita Coco: Which Beverage Stock Offers Better Growth?

In the fast-evolving beverage market, PepsiCo Inc. PEP and The Vita Coco Company Inc. COCO represent two very different paths to consumer relevance and two vastly different positions on the market

Here's How V.F. Corp. Stock is Poised Ahead of Q3 Earnings
Here's How V.F. Corp. Stock is Poised Ahead of Q3 Earnings

V.F. Corporation VFC is likely to register year-over-year bottom and top-line declines when it posts third-quarter fiscal 2026 earnings on Jan. 28, before the opening bell. The Zacks Consensus

COF Falls on Q4 Earnings Miss as Costs Rise Y/Y, Announces Brex Deal
COF Falls on Q4 Earnings Miss as Costs Rise Y/Y, Announces Brex Deal

Shares of Capital One COF lost 2.9% in after-hour trading following the announcement of worse-than-expected fourth-quarter 2025 results. Adjusted earnings of $3.86 per share missed the Zacks

Alcoa vs. Ryerson: Which Aluminum Stock Should You Bet On?
Alcoa vs. Ryerson: Which Aluminum Stock Should You Bet On?

Alcoa Corporation AA and Ryerson Holding Corporation RYI are two prominent players in the aluminum sector with global operations and diversified portfolios. With aluminum prices remaining high

Ericsson Q4 Earnings Beat Estimates Despite Lower Revenues
Ericsson Q4 Earnings Beat Estimates Despite Lower Revenues

Ericsson ERIC reported strong fourth-quarter 2025 results, with both the earnings and revenues beating the Zacks Consensus Estimate. However, ERIC’s top line was affected by weakness in the North

4 Stocks Trading Near 52-Week High With More Upside Potential
4 Stocks Trading Near 52-Week High With More Upside Potential

Investors generally consider a stock's 52-week high a good criterion for an entry or exit point. Stocks touching new 52-week highs are often predisposed to profit-taking, resulting in pullbacks and

Northrim BanCorp (NRIM) Lags Q4 Earnings Estimates
Northrim BanCorp (NRIM) Lags Q4 Earnings Estimates

Northrim BanCorp (NRIM) came out with quarterly earnings of $0.54 per share, missing the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.49 per share a year ago. These

FFIV Gears Up to Report Q1 Earnings: What's in the Cards?
FFIV Gears Up to Report Q1 Earnings: What's in the Cards?

F5 Inc. FFIV is scheduled to report first-quarter fiscal 2026 results on Jan. 27, after market close.

For the first quarter of fiscal 2026, F5 projects non-GAAP earnings per share (EPS) in the range

Realty Income: The Monthly Paycheck Winner of 2026: https://www.marketbeat.com/logos/articles/med_20260122103309_realty-income-the-monthly-paycheck-winner-of-2026.png
Realty Income: The Monthly Paycheck Winner of 2026

The first few weeks of 2026 have been a wake-up call for investors who became accustomed to the smooth sailing of previous rallies. Markets are currently digesting a cocktail of economic anxiety

Rising Consulting Demand Aids Charles River Amid Low Liquidity
Rising Consulting Demand Aids Charles River Amid Low Liquidity

Charles River Associates’ CRAI top line is expected to gain from a surge in demand for specialized advisory services. The company’s high-quality consulting services and the global talent workforce

BKR to Report Q4 Earnings: Here's What You Need to Know
BKR to Report Q4 Earnings: Here's What You Need to Know

Baker Hughes BKR is set to report fourth-quarter 2025 results on Jan. 25, after the closing bell.

Let us examine the factors that are expected to have impacted this oilfield service player’s

Pre-Markets Lower Ahead of Massive Polar Vortex: https://staticx-tuner.zacks.com/images/articles/main/8d/143430.webp
Pre-Markets Lower Ahead of Massive Polar Vortex

Friday, January 23rd, 2026It’s been an eventful week on Wall Street, with plenty of harbingers for market moves including President Trump’s reversal on Greenland, accommodating economic prints on

ETFs to Watch as Silver's Upward Momentum Continues
ETFs to Watch as Silver's Upward Momentum Continues

Silver prices have climbed to fresh highs, supported by rising safe-haven demand amid a fragile geopolitical backdrop and renewed transatlantic trade frictions, reinforcing investor interest and

Best Growth Stocks to Buy for January 23rd
Best Growth Stocks to Buy for January 23rd

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today January 23rd:

Ciena CIEN: This company which is a leading provider of optical networking

SSB Q4 Earnings Beat on Growth in NII, Fee Revenues, Provisions Rise
SSB Q4 Earnings Beat on Growth in NII, Fee Revenues, Provisions Rise

SouthState Corporation SSB reported fourth-quarter 2025 adjusted earnings per share of $2.47, which surpassed the Zacks Consensus Estimate of $2.30. Also, the bottom line increased 28% from the

Biotech ETF (XBI) Hits New 52-Week High
Biotech ETF (XBI) Hits New 52-Week High

For investors seeking momentum, State Street SPDR S&P Biotech ETF XBI is probably on the radar. The fund just hit a 52-week high and has risen 98.15% from its 52-week low price of $66.66/share.

But